Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 9/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.47 |
| ▸ | MTOR | P42345 | 5/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.39 |
| ▸ | CCR9 | P51686 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809132 | 0.93 | PIK3CA (0.44) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL14809513 | 0.92 | BRAF (0.46) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL14809305 | 0.91 | HDAC3 (0.47) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL14716129 | 0.88 | PIK3CB (0.44) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL16506281 | 0.87 | BRAF (0.52) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL14809608 | 0.87 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL14809340 | 0.86 | PIK3CA (0.44) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL14809543 | 0.85 | PIK3CA (0.55) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL14785852 | 0.83 | RAB9A (0.49) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR | |
| SCHEMBL14809399 | 0.83 | HDAC3 (0.49) | PIK3CAPIK3CBPIK3CGPIK3CDMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757885-B1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2017-03-15 | — | — | EP | claimed |
| US-9249110-B2 | Substituted quinoxalines as B-raf kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | claimed |
| US-20150057276-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-02-26 | — | — | US | claimed |
| EP-2757885-A1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-30 | — | — | EP | claimed |
| WO-2013043935-A1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-28 | — | — | WO | claimed |
| EP-2757885-B1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9249110-B2 | Substituted quinoxalines as B-raf kinase inhibitors | NEUPHARMA, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150057276-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
| EP-2757885-A1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043935-A1 | CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057276-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | PIK3CA 2/4885PIK3CB 9/4885PIK3CG 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.